相关实验视频
Updated: Jan 9, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
877
世界卫生组织-EML 2025名单上的GLP-1受体激动剂:重大突破受到持续挑战的限制
1Department of Pharmacology, SRM Medical College Hospital and Research Centre, SRMIST, Kattankulathur, Chengalpattu, Tamil Nadu 603 203 India.
Journal of diabetes and metabolic disorders
|December 8, 2025
概括
世界卫生组织 世界卫生组织
科学领域:
- 全球健康 全球健康
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
背景情况:
- 世界卫生组织 (WHO) 更新其基本药物清单 (EML),以反映全球卫生优先事项.
- 第24次EML和第10次EMLc包括20种用于糖尿病和癌症等疾病的新药.
- 现在已经承认新的糖尿病和肥胖药物,包括GLP-1受体激动剂和蒂尔泽帕提德.
研究的目的:
- 突出世卫组织更新的基本药物清单 (EML) 的重要性.
- 强调将新型治疗方法纳入2型糖尿病 (T2DM) 和肥胖的治疗.
- 讨论对全球非传染性疾病 (NCD) 获取和管理的影响.
主要方法:
- 世界卫生组织第24次EML和第10次EMLc更新的分析.
- 审查新加入药物的治疗益处.
- 评估低收入和中等收入国家 (LMICs) 对获取机会的潜在影响.
主要成果:
- 更新的EML包括GLP-1受体激动剂 (塞马格卢提德,利拉格卢提德,杜拉格卢提德) 和蒂尔泽帕提德用于T2DM和肥胖症.
- 这些药物在血糖控制,心血管/脏结果和减肥方面显示出显著的益处.
- 包容旨在改善LMICs中获得这些重要治疗的机会.
结论:
- 将新的糖尿病和肥胖药物列入EML是迈向公平获取的重要一步.
- 这符合可持续发展目标3.4,即减少非传染性疾病死亡率.
- 实施中的挑战,如成本和基础设施,需要国家政策干预,以获得成功的公共卫生结果.
相关概念视频
Glucagon-like Receptor Agonists
820
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
820
Oral Hypoglycemic Agents: Glinides
572
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
572
Dipeptidyl Peptidase 4 Inhibitors
559
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
559
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
509
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
509
Oral Hypoglycemic Agents: Biguanides and Glitazones
565
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
565
G Protein-coupled Receptors
16.3K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
16.3K

